Skip to main content

Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis: As Good as it Gets?

Clinical Reviews in Allergy & Immunology volume 34, pages 26–31 (2008)Cite this article

Abstract

Anti-citrullinated protein antibodies (ACPAs) have recently emerged as sensitive and specific serological markers of rheumatoid arthritis (RA), providing superior alternative of the rheumatoid factor (RF) test in the laboratory diagnostics of RA. The first members of this autoantibody family were anti-perinuclear factor (APF) and anti-keratin antibodies (AKA). It became evident that both APF and AKA recognize citrullinated epitopes of filaggrin. Citrullination is a post-translational modification of arginine by deimination, physiologically occurring during apoptosis, inflammation or keratinization. The presence of several citrullinated proteins has been demonstrated in the RA synovium. The identification of citrullinated epitopes as targets for anti-filaggrin antibodies led to the development of the first and later second generation anti-cyclic citrullinated peptide (anti-CCP) antibody assays. The widely used anti-CCP2 assays have high diagnostic sensitivity and specificity, and they also show important predictive and prognostic value in RA. The anti-Sa antibody has been identified a decade ago; however, recent studies confirmed that anti-Sa is directed against citrullinated vimentin, hence it is a new member of the family of ACPAs. The newly developed anti-mutated citrullinated vimentin (anti-MCV) assay has similar diagnostic performance than the anti-CCP2 ELISA; however, the diagnostic spectrum of the anti-MCV test is somewhat different from that of anti-CCP2. It’s especially useful in the diagnosis of RA in RF and anti-CCP2 seronegative patients. The combined application of anti-CCP2 and anti-MCV assays can improve the laboratory diagnostics of RA. The family of ACPAs is expected to expand; there is an increasing need for developing new diagnostic strategies after careful evaluation of the characteristics of the available assays.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Alamanos Y, Drosos AA (2005) Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 4:130–136

    PubMed  Article  Google Scholar 

  2. Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358:903–911

    PubMed  Article  CAS  Google Scholar 

  3. Goldblatt F, Isenberg DA (2005) New therapies for rheumatoid arthritis. Clin Exp Immunol 140:195–204

    PubMed  Article  CAS  Google Scholar 

  4. Hassfeld W, Steiner G, Graninger W, Witzmann G, Schweitzer H, Smolen JS (1993) Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br J Rheumatol 32:199–203

    PubMed  Article  CAS  Google Scholar 

  5. Deprés N, Boire G, Lopez-Longo FJ, Ménard HA (1994) The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol 21:1027–1033

    Google Scholar 

  6. Nienhuis RLF, Mandema EA (1964) A new serum factor in patients with rheumatoid arthritis. The antiperinuclear factor. Ann Rheum Dis 23:302–305

    PubMed  CAS  Google Scholar 

  7. Van Schaardenburg D, Lagaay AM, Otten HG, Breedveld FC (1993) The relation between class-specific serum rheumatoid factors and age in the general population. Br J Rheumatol 32:546–549

    PubMed  Article  Google Scholar 

  8. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS (2000) Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2:236–243

    PubMed  Article  CAS  Google Scholar 

  9. Visser H, Gelinck LB, Kampfraath AH, Beedveld FC, Hazes JM (1996) Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Ann Rheum Dis 55:157–161

    PubMed  CAS  Google Scholar 

  10. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101:273–281

    PubMed  Article  CAS  Google Scholar 

  11. Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, Simon M, Senshu T, Masson-Bessiere C, Jolivet-Reynaud C, Jolivet M, Serre G (1999) The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 162:585–594

    PubMed  CAS  Google Scholar 

  12. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163

    PubMed  Article  CAS  Google Scholar 

  13. Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ (1979) Anti-keratin antibodies in rheumatoid arthritis. Br Med J 2:97–99

    PubMed  CAS  Article  Google Scholar 

  14. Simon M, Girbal E, Sebbag M, Gomes-Daudrix V, Vincent C, Salama G, Serre G (1993) The cytokeratin filament-aggregating protein filaggrin is the target of the so-called “antikeratin antibodies,” autoantibodies specific for rheumatoid arthritis. J Clin Invest 92:1387–1393

    PubMed  CAS  Google Scholar 

  15. Vincent C, Simon M, Sebbag M, Girbal-Neuhauser E, Durieux JJ, Cantagrel A, Fournie B, Mazieres B, Serre G (1998) Immunoblotting detection of autoantibodies to human epidermis filaggrin: a new diagnostic test for rheumatoid arthritis. J Rheumatol 25:838–846

    PubMed  CAS  Google Scholar 

  16. Vincent C, Nogueira L, Sebbag M, Chapuy-Regaud S, Arnaud M, Letourneur O, Rolland D, Fournie B, Cantagrel A, Jolivet M, Serre G (2002) Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis. Arthritis Rheum 46:2051–2058

    PubMed  Article  CAS  Google Scholar 

  17. van der Helm-van Mil AH, Wesoly JZ, Huizinga TW (2005) Understanding the genetic contribution to rheumatoid arthritis. Curr Opin Rheumatol 17:299–304

    PubMed  Article  Google Scholar 

  18. van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E, van Venrooij WJ, Verweij CL, Toes RE, de Vries RR (2004) Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 50:2113–2121

    PubMed  Article  CAS  Google Scholar 

  19. Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA, Jawaheer D, Schreuder GM, Wener M, Breedveld FC, Ahmad N, Lum RF, de Vries RR, Gregersen PK, Toes RE, Criswell LA (2005) Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 52:3433–3438

    PubMed  Article  CAS  Google Scholar 

  20. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ (2003) PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 25:1106–1118

    PubMed  Article  CAS  Google Scholar 

  21. Vossenaar ER, Radstake TR, van der Heijden A, van Mansum MA, Dieteren C, de Rooij DJ, Barrera P, Zendman AJ, van Venrooij WJ (2004) Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 63:373–381

    PubMed  Article  CAS  Google Scholar 

  22. Chang X, Yamada R, Suzuki A, Sawada T, Yoshino S, Tokuhiro S, Yamamoto K (2005) Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatology (Oxford) 44:40–50

    Article  CAS  Google Scholar 

  23. Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij WJ, Tak PP (2004) The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 50:3485–3494

    PubMed  Article  CAS  Google Scholar 

  24. Takizawa Y, Suzuki A, Sawada T, Ohsaka M, Inoue T, Yamada R, Yamamoto K (2006) Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids. Ann Rheum Dis 65:1013–1020

    PubMed  Article  CAS  Google Scholar 

  25. Asaga H, Yamada M, Senshu T (1998) Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages. Biochem Biophys Res Commun 243:641–646

    PubMed  Article  CAS  Google Scholar 

  26. Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM (2003) Vimentin is secreted by activated macrophages. Nature Cell Biol 5:59–63

    PubMed  Article  CAS  Google Scholar 

  27. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, Serre G (2001) The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 166:4177–4184

    PubMed  CAS  Google Scholar 

  28. Sebbag M, Moinard N, Auger I, Clavel C, Arnaud J, Nogueira L, Roudier, Serre G (2006) Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins. Eur J Immunol 36:2250–2263

    PubMed  Article  CAS  Google Scholar 

  29. Chang X, Yamada R, Suzuki A, Kochi Y, Sawada T, Yamamoto K (2005) Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology 44:1374–1382

    PubMed  Article  CAS  Google Scholar 

  30. Baeten D, Peene I, Union A, Meheus L, Sebbag M, Serre G, Veys EM, De Keyse F (2001) Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum 44:2255–2262

    PubMed  Article  CAS  Google Scholar 

  31. Chapuy-Regaud S, Sebbag M, Baeten D, Clavel C, Foulquier C, De Keyser F, Serre G (2005) Fibrin deimination in synovial tissue is not specific for rheumatoid arthritis but commonly occurs during synovitides. J Immunol 174:5057–5064

    PubMed  CAS  Google Scholar 

  32. Van Esch WJ, Reparon-Schuijt CC, Hamstra HJ, Van Kooten C, Logtenberg T, Breedveld FC, Verweij CL (2003) Human IgG Fc-binding phage antibodies constructed from synovial fluid CD38+ B cells of patients with rheumatoid arthritis show the imprints of an antigen-dependent process of somatic hypermutation and clonal selection. Clin Exp Immunol 131:364–376

    PubMed  Article  Google Scholar 

  33. Masson-Bessiere C, Sebbag M, Durieux JJ, Nogueira L, Vincent C, Girbal-Neuhauser E, Durroux R, Cantagrel A, Serre G (2000) In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol 119:544–552

    PubMed  Article  CAS  Google Scholar 

  34. Reparon-Schuijt CC, van Esch WJ, van Kooten C, Schellekens GA, de Jong BA, van Venrooij WJ, Breedveld FC, Verweij CL (2001) Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum 44:41–47

    PubMed  Article  CAS  Google Scholar 

  35. Lundberg K, Nijenhuis S, Vossenaar ER, Palmblad K, van Venrooij WJ, Klareskog L, Zendman AJ, Harris HE (2005) Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 7:R458–R467

    PubMed  Article  CAS  Google Scholar 

  36. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, Holers VM (2006) Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 116:961–973

    PubMed  Article  CAS  Google Scholar 

  37. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581

    PubMed  Article  CAS  Google Scholar 

  38. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR (2006) The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 54:1117–1121

    PubMed  Article  CAS  Google Scholar 

  39. Irigoyen P, Lee AT, Wener MH, Li W, Kern M, Batliwalla F (2005) Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum 52:3813–3818

    PubMed  Article  CAS  Google Scholar 

  40. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW (2002) How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46:357–365

    PubMed  Article  Google Scholar 

  41. Kapitány A, Szabó Z, Lakos G, Aleksza M, Végvári A, Soós L, Karányi Z, Sipka S, Szegedi G, Szekanecz Z (2006) Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in patients with rheumatoid arthritis. Ann Rheum Dis 65(Suppl II):299

    Google Scholar 

  42. Roudier J (2000) Association of MHC and rheumatoid arthritis. Association of RA with HLA-DR4: the role of repertoire selection. Arthritis Res 2:217–220

    PubMed  Article  CAS  Google Scholar 

  43. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E (2003) Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 171:538–541

    PubMed  CAS  Google Scholar 

  44. Klareskog L, Padyukov L, Lorentzen J, Alfredsson L (2006) Mechanisms of disease: genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nature Clin Pract Rheumatol 2:425–433

    Article  CAS  Google Scholar 

  45. Smolen JS (1996) Autoantibodies in rheumatoid arthritis. In: van Venrooij WJ, Maini RN (eds) Manual of biological markers of disease. Kluwer, Dordrecht, pp 1–18

    Google Scholar 

  46. Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, Durieux JJ, Serre G (1995) The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 95:2672–2679

    PubMed  CAS  Google Scholar 

  47. Simon M, Girbal E, Sebbag M, Gomes-Daudrix V, Vincent C, Salama G, Serre G (1993) The cytokeratin filament-aggregating protein filaggrin is the target of the so-called “antikeratin antibodies,” autoantibodies specific for rheumatoid arthritis. J Clin Invest 92:1387–1393

    PubMed  CAS  Article  Google Scholar 

  48. Palosuo T, Lukka M, Alenius H, Kalkkinen N, Aho K, Kurki P, Heikkila R, Nykanen M, von Essen R (1998) Purification of filaggrin from human epidermis and measurement of antifilaggrin autoantibodies in sera from patients with rheumatoid arthritis by an enzyme-linked immunosorbent assay. Int Arch Allergy Immunol 115:294–302

    PubMed  Article  CAS  Google Scholar 

  49. Aho K, Palosuo T, Lukka M, Kurki P, Isomaki H, Kautiainen H, von Essen R (1999) Antifilaggrin antibodies in recent-onset arthritis. Scand J Rheumatol 28:113–116

    PubMed  Article  CAS  Google Scholar 

  50. Vallbracht I, Rieber J, Oppermann M, Forger F, Siebert U, Helmke K (2004) Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63:1079–1084

    PubMed  Article  CAS  Google Scholar 

  51. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749

    PubMed  Article  CAS  Google Scholar 

  52. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64:196–201

    PubMed  Article  CAS  Google Scholar 

  53. Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 42:677–680

    Article  CAS  Google Scholar 

  54. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B (2003) Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62:120–126

    PubMed  Article  CAS  Google Scholar 

  55. Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63:1085–1089

    PubMed  Article  CAS  Google Scholar 

  56. Mikuls TR, O’Dell JR, Stoner JA, Parrish LA, Arend WP, Norris JM, Holers VM (2004) Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 50:3776–3782

    PubMed  Article  CAS  Google Scholar 

  57. Vincent C, Nogueira L, Clavel C, Sebbag M, Serre G (2005) Autoantibodies to citrullinated proteins: ACPA. Autoimmunity 38:17–24

    PubMed  Article  CAS  Google Scholar 

  58. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380–386

    PubMed  Article  Google Scholar 

  59. Hayem G, Chazerain P, Combe B, Elias A, Haim T, Nicaise P, Benali K, Eliaou JF, Kahn MF, Sany J, Meyer O (1999) Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol 26:7–13

    PubMed  CAS  Google Scholar 

  60. Menard HA, Lapointe E, Rochdi MD, Zhou ZJ (2000) Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Res 2:429–432

    PubMed  Article  CAS  Google Scholar 

  61. Boire G, Cossette P, de Brum-Fernandes AJ, Liang P, Niyonsenga T, Zhou ZJ, Carrier N, Daniel C, Menard HA (2005) Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are notequivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 7:R592–R603

    PubMed  Article  CAS  Google Scholar 

  62. Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T, van Venrooij WJ, Menard HA (2004) Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 6:R142–R150

    PubMed  Article  CAS  Google Scholar 

  63. Lakos G, Soos L, Szabo Z, Fekete A, Zeher M, Horváth I, Dankó K, Kapitány A, Szegedi G, Sipka S, Szekanecz Z (2006) Antibodies directed against mutated citrullinated vimentin (anti-MCV) are more sensitive serological markers of rheumatoid arthritis than anti-CCP. Ann Rheum Dis 65(Suppl II):151

    Google Scholar 

  64. Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M (2006) Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 8:R119

    PubMed  Article  CAS  Google Scholar 

  65. Rodriguez-Mahou M, López-Longo FJ, Sanchez-Ramon S, Estecha A, Garcia-Segovia A, Rodriguez-Molina JJ, Carreno L, Fernandez-Cruz E (2006) Association of anti-cyclic citrullinated peptide and anti-Sa/citrullinated vimentin autoantibodies in rheumatoid arthritis. Arthritis Care Res 55:657–661

    Article  CAS  Google Scholar 

  66. Hill JA, Al-Bishri J, Gladman DD, Cairns E, Bell DA (2006) Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. J Rheumatol 33:2115–2119

    PubMed  CAS  Google Scholar 

  67. Vander Cruyssen B, Cantaert T, Nogueira L, Clavel C, De Rycke L, Dendoven A, Sebag M, Deforce D, Vincent C, Elewaut D, Serre G, De Keyser F (2006) Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays. Arthritis Res Ther 8:R122

    Article  CAS  Google Scholar 

  68. Nielen MM, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L, Dijkmans BA, Hamann D (2005) Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 64:1199–1204

    PubMed  Article  CAS  Google Scholar 

  69. Auger I, Sebbag M, Vincent C, Balandraud N, Guis S, Nogueira L, Svensson B, Cantagrel A, Serre G, Roudier J (2005) Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen. Arthritis Rheum 52:3424–3432

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgement

This work was supported by grant no. T 048541 from the Hungarian National Scientific Research Fund (OTKA; Z.S.).

Author information

Affiliations

  1. Division of Rheumatology, 3rd Department of Medicine, Medical and Health Science Center, University of Debrecen, 22 Moricz Street, Debrecen, H-4004, Hungary

    Zoltán Szekanecz, Lilla Soós, Zoltán Szabó, Anikó Végvári, Gabriella Szücs & Sándor Szántó

  2. Laboratory of Immunology, 3rd Department of Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary

    Andrea Fekete, Anikó Kapitány, Sándor Sipka & Gabriella Lakos

Authors
  1. Zoltán Szekanecz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lilla Soós
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zoltán Szabó
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrea Fekete
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anikó Kapitány
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anikó Végvári
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sándor Sipka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gabriella Szücs
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sándor Szántó
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Gabriella Lakos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zoltán Szekanecz.

Additional information

Zoltán Szekanecz and Lilla Soós with equal contribution.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Szekanecz, Z., Soós, L., Szabó, Z. et al. Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis: As Good as it Gets?. Clinic Rev Allerg Immunol 34, 26–31 (2008). https://doi.org/10.1007/s12016-007-8022-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-007-8022-5

Keywords

  • Rheumatoid arthritis
  • Anti-mutated citrullinated vimentin
  • Anti-CCP2